MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. is registering 751,879 shares of common stock for resale by PoC Capital LLC, which received the shares under a Clinical Trial Funding Agreement. Resales may occur from time to time after the registration statement becomes effective, at prevailing market prices, prices related to prevailing market prices or privately negotiated prices; PoC may sell any, all or none. MAIA will not receive proceeds from the resales.
Separately, PoC agreed to provide $1,000,000 following the prospectus date, to be applied to expenses for MAIA studies evaluating THIO in patients with cancer. MAIA also states there is substantial doubt about its ability to continue as a going concern and that it will need substantial additional funding.
MAIA Biotechnology, Inc. (MAIA) director, chief executive officer, and ten percent owner Vlad Vitoc reported purchasing 73,000 shares of common stock on September 14, 2026 in an open-market or private transaction at $1.37 per share. Following this purchase, he holds 1,049,121 shares directly. An additional 210,100 shares are reported as indirectly owned through his spouse, with beneficial ownership disclaimed except for his pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero purchased additional Common Stock in an open-market or private transaction on September 10, 2026. He bought 37,595 shares at a reported price of $1.3171 per share, bringing his directly held stake to 773,296 shares after the transaction.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported a series of open-market purchases of the company’s common stock. On August 26–28, 2026, he purchased a total of 133,790 shares in three transactions at per-share prices between $1.35 and $1.39, with no sales reported.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero purchased common stock in an open-market or private transaction. On 2026-08-24, he bought 1,794 shares of MAIA common stock at a price of $1.33 per share, bringing his directly held position to 601,911 shares of common stock following the transaction.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported purchasing common stock in an open market or private transaction. On 2026-08-20, he bought 11,899 shares at $1.37 per share, bringing his directly held position to 600,117 shares following the transaction. The filing indicates the Rule 10b5-1 checkbox was not selected.
MAIA Biotechnology, Inc. (MAIA) has filed a shelf registration on Form S-3 to offer, from time to time, up to $150,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights and units. This is a primary, mixed-shelf program using a continuous or delayed offering format.
Under Rule 415(a)(6), the filing carries forward $94,010,093.10 of unsold securities from a 2023 shelf, with filing fees of $10,359.92 already paid. MAIA’s common stock trades on NYSE American under “MAIA,” closing at $1.39 on August 19, 2026, with 60,834,206 shares outstanding as of August 20, 2026.
MAIA is a clinical-stage biopharmaceutical company focused on targeted immunotherapies for cancer, led by ateganosine (THIO) for non-small cell lung cancer, now in Phase 2 (THIO-101) and a pivotal Phase 3 (THIO-104), with additional Phase 2 trials planned in HCC, CRC and SCLC. The company discloses ongoing losses, substantial additional funding needs, and substantial doubt about its ability to continue as a going concern, alongside extensive clinical, regulatory, intellectual-property and stock-price risks.
Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of 3,030,845 shares of MAIA Biotechnology, Inc. common stock. This represents 4.9% of the common stock outstanding, based on 60,800,758 shares outstanding as of May 11, 2026.
The shares are held by two private funds for the benefit of their investors, over which Solas acts as investment manager and sub-adviser, and Golden serves as Portfolio Manager. Both Solas and Golden report shared voting and dispositive power over all 3,030,845 shares and no sole voting or dispositive power. The funds themselves expressly disclaim beneficial ownership of the reported securities.
MAIA Biotechnology, Inc., a clinical-stage oncology company focused on telomere-targeting immunotherapy candidate ateganosine (THIO) for non-small cell lung cancer, reported higher operating spending and net losses for the three and six months ended June 30, 2026. For the six‑month period, research and development expenses were $9.16 million and general and administrative expenses were $6.10 million, driving a net loss of $14.31 million compared with $9.86 million a year earlier.
Cash strengthened significantly following March 2026 equity offerings, with cash of $27.60 million and working capital of $21.98 million at June 30, 2026, versus cash of $8.66 million at year‑end 2025. Net cash used in operating activities was $12.06 million for the six months, partially offset by $30.99 million of net cash from financing, mainly a confidentially marketed public offering. Total assets were $28.24 million and warrant liabilities measured at fair value were $1.31 million.